ABIM MOC

Livestream: The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…

The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face…

Maintaining Patient QoL through Optimal Management of ADC-Associated AEs

Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…

Clinical Trial Data with ADCs: New Options for HER2-Negative MBC

The rapidly shifting therapeutic landscape for HER2-negative metastatic breast cancer (MBC) challenges clinicians to stay up-to-date on emerging clinical trial data, as well as recommendations on therapy selection and sequencing. Unfamiliarity with antibody-drug conjugate (ADC) treatment…

ADCs and Chemotherapy: More Different Than You Might Expect in HER2-Negative MBC

Antibody-drug conjugates (ADCs) have recently been approved to treat HER2-negative metastatic breast cancer (MBC). In an ADC, a cytotoxic chemotherapeutic agent is conjugated to a monoclonal antibody directed against a tumor-associated antigen. Conjugation fundamentally alters tissue…

Emerging Considerations for the Role of Biomarker-Driven Immunotherapy in Upper GI Cancers

Upper gastrointestinal (GI) cancers are often undetected until late stages, leading to a poor prognosis. Treatment may be delayed or inappropriately assigned due to a lack of robust biomarker testing. To optimize patient outcomes, oncology clinicians…

Advancing Cervical Cancer Care: Navigating New Therapies, Guidelines, and Patient-Centric Approaches

Delayed diagnosis of cervical cancer often leads to poor prognosis and lower survival rates, especially in advanced stages. Recent therapeutic advancements, including immune-checkpoint inhibitors and antibody-drug conjugates (ADCs), offer new hope for managing advanced cervical cancer….

MEK Inhibitors in Neurofibromatosis Type 1: Latest Advances and Real-world Applications in NF1-PN Management

Neurofibromatosis type 1 (NF1) treatment options and management strategies are evolving, and the multiplicity of near- and long-term clinical manifestations makes diagnosis and management of the disease complex. The development of plexiform neurofibromas (PNs) further negatively…

The Promise of Folate Receptor Alpha-Targeting ADCs for Platinum-Resistant Ovarian Cancer

Ovarian cancer typically responds well to initial platinum-based chemotherapy treatment. However, most tumors subsequently relapse and eventually become resistant, for which the prognosis is poor and no therapeutic options which have shown substantial OS benefit. Further,…

Emergency Care of Patients with Cancer Receiving CAR T-cell and Bispecific Antibody Immunotherapies Experiencing Serious Adverse Events

As the use of immunotherapies for the treatment of cancer expands, emergency medicine (EM) clinicians will need a further understanding of their mechanisms of action (MOAs) to better guide diagnosis and treatment of patients who present…